It Is All about (U)biquitin: Role of Altered Ubiquitin-Proteasome System and UCHL1 in Alzheimer Disease

Oxidative Medicine and Cellular Longevity

Volumn 2016, Issue , 2016, Pages

  Tramutola, Antonella ^a   Di Domenico, Fabio ^a   Barone, Eugenio ^a,b   Perluigi, Marzia ^a   Butterfield, D Allan ^c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSIDAD AUTÓNOMA DE CHILE   (Chile)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FREE RADICALS; NEURODEGENERATIVE DISEASES; OXIDATION;

ALZHEIMER DISEASE; CELLULAR COMPONENTS; OXIDATIVE MODIFICATION; PROTEIN STRUCTURES; PROTEOLYTIC SYSTEM; RADICAL-MEDIATED DAMAGES; STRESS-INDUCED DAMAGE; UBIQUITIN-PROTEASOME SYSTEM;

PROTEINS;

ADENOSINE TRIPHOSPHATE; DEUBIQUITINASE; MUTANT PROTEIN; POLYUBIQUITIN; PROTEASOME; TAU PROTEIN; UBB 1 PROTEIN; UBIQUITIN; UBIQUITIN CARBOXYTERMINAL HYDROLASE L1; UBIQUITIN THIOLESTERASE; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; OXYGEN; UCHL1 PROTEIN, HUMAN;

ALZHEIMER DISEASE; HUMAN; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PROTEIN AGGREGATION; PROTEIN FUNCTION; PROTEIN HOMEOSTASIS; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; UBIQUITIN PROTEASOME SYSTEM; UBIQUITINATION; UNFOLDED PROTEIN RESPONSE; AGING; ANIMAL; CELL NUCLEUS; CHEMISTRY; CYTOSOL; HOMEOSTASIS; METABOLISM; MOUSE; MUTATION; OXIDATION REDUCTION REACTION; PROTEIN DENATURATION; PROTEIN FOLDING;

ADENOSINE TRIPHOSPHATE; AGING; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; CELL NUCLEUS; CYTOSOL; HOMEOSTASIS; HUMANS; MICE; MUTATION; OXIDATION-REDUCTION; OXIDATIVE STRESS; OXYGEN; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN DENATURATION; PROTEIN FOLDING; UBIQUITIN; UBIQUITIN THIOLESTERASE;

EID: 84961344015     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2016/2756068     Document Type: Review

References (107)

1. K. Cuanalo-Contreras, A. Mukherjee, and C. Soto, Role of protein misfolding and proteostasis deficiency in protein misfolding diseases and aging, International Journal of Cell Biology, vol. 2013, Article ID 638083, 10 pages, 2013.
2. D. Ortuño-Sahagún, M. Pallas, and A. E. Rojas-Mayorqu?n, Oxidative stress in aging: advances in proteomic approaches, OxidativeMedicine and Cellular Longevity, vol. 2014,Article ID 573208, 18 pages, 2014.
3. T. Grune, T. Reinheckel, and K. J. A. Davies, Degradation of oxidized proteins in mammalian cells, The FASEB Journal, vol. 11, no. 7, pp. 526-534, 1997.
4. N. P. Dantuma and L. C. Bott, The ubiquitin-proteasome system in neurodegenerative diseases: precipitating factor, yet part of the solution, Frontiers in Molecular Neuroscience, vol. 7, article 70, 2014.
5. A. Ciechanover and P. Brundin, The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg, Neuron, vol. 40, no. 2, pp. 427-446, 2003.
6. N. Breusing and T. Grune, Regulation of proteasome-mediated protein degradation during oxidative stress and aging, Biological Chemistry, vol. 389, no. 3, pp. 203-209, 2008.
7. T. J. A. Hohn and T. Grune, The proteasome and the degradation of oxidized proteins: part III-Redox regulation of the proteasomal system, Redox Biology, vol. 2, no. 1, pp. 388-394, 2014.
8. U. B. Pandey, Z. Nie, Y. Batlevi et al. , HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS, Nature, vol. 447, no. 7146, pp. 859-863, 2007.
9. M. Milani, T. Rzymski, H. R. Mellor et al. , The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib, Cancer Research, vol. 69, no. 10, pp. 4415-4423, 2009.
10. T. Pan, S. Kondo, W. Zhu, W. Xie, J. Jankovic, and W. Le, Neuroprotection of rapamycin in lactacystin-induced neurodegeneration via autophagy enhancement, Neurobiology of Disease, vol. 32, no. 1, pp. 16-25, 2008.
11. V. I. Korolchuk, F. M. Menzies, and D. C. Rubinsztein, Mechanisms of cross-talk between the ubiquitin-proteasome and autophagy-lysosome systems, FEBS Letters, vol. 584, no. 7, pp. 1393-1398, 2010.
12. M. Perluigi, F. Di Domenico, and D. A. Butterfield, mTOR signaling in aging and neurodegeneration: at the crossroad between metabolism dysfunction and impairment of autophagy, Neurobiology of Disease, 2015.
13. T. Jung and T. Grune, The proteasome and its role in the degradation of oxidized proteins, IUBMB Life, vol. 60, no. 11, pp. 743-752, 2008.
14. A. Ciechanover, The unravelling of the ubiquitin system, Nature Reviews Molecular Cell Biology, vol. 16, no. 5, pp. 322-324, 2015.
15. Y. A. Sulistio and K. Heese, The ubiquitin-proteasome system and molecular chaperone deregulation in Alzheimers disease, Molecular Neurobiology, 2015.
16. Q. Huang and M. E. Figueiredo-Pereira, Ubiquitin/proteasome pathway impairment in neurodegeneration: therapeutic implications, Apoptosis, vol. 15, no. 11, pp. 1292-1311, 2010.
17. K. -L. Limand J. M. M. Tan, Role of the ubiquitin proteasome system in Parkinsons disease, BMC Biochemistry, vol. 8, supplement 1, article S13, 2007.
18. S. Grimm, A. Hohn, and T. Grune, Oxidative protein damage and the proteasome,Amino Acids, vol. 42,no. 1, pp. 23-38, 2012.
19. T. Jung, B. Catalgol, and T. Grune, The proteasomal system, Molecular Aspects of Medicine, vol. 30, no. 4, pp. 191-296, 2009.
20. E. M. Blalock, J. W. Geddes, K. C. Chen, N. M. Porter, W. R. Markesbery, and P. W. Landfield, IncipientAlzheimers disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses, Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 7, pp. 2173-2178, 2004.
21. T. Watanabe, Y. Hikichi, A. Willuweit, Y. Shintani, and T. Horiguchi, FBL2 regulates amyloid precursor protein (APP) metabolism by promoting ubiquitination-dependent APP degradation and inhibition of APP endocytosis, Journal of Neuroscience, vol. 32, no. 10, pp. 3352-3365, 2012.
22. M. Koegl, T. Hoppe, S. Schlenker, H. D. Ulrich, T. U. Mayer, and S. Jentsch, A novel ubiquitination factor, E4, is involved in multiubiquitin chain assembly, Cell, vol. 96, no. 5, pp. 635-644, 1999.
23. J. S. Thrower, L. Hoffman, M. Rechsteiner, and C. M. Pickart, Recognition of the polyubiquitin proteolytic signal, The EMBO Journal, vol. 19, no. 1, pp. 94-102, 2000.
24. E. J. Bennett and J. W. Harper, DNA damage: ubiquitin marks the spot, Nature Structural andMolecular Biology, vol. 15, no. 1, pp. 20-22, 2008.
25. J. N. Hislop and M. von Zastrow, Role of ubiquitination in endocytic trafficking of G-protein-coupled receptors, Traffic, vol. 12, no. 2, pp. 137-148, 2011.
26. C. Raiborg and H. Stenmark, The ESCRT machinery in endosomal sorting of ubiquitylatedmembrane proteins, Nature, vol. 458, no. 7237, pp. 445-452, 2009.
27. J. H. Kim, K. C. Park, S. S. Chung, O. Bang, and C. H. Chung, Deubiquitinating enzymes as cellular regulators, Journal of Biochemistry, vol. 134, no. 1, pp. 9-18, 2003.
28. F. Di Domenico, E. Head, D. A. Butterfield, and M. Perluigi, Oxidative stress and proteostasis network: culprit and casualty of Alzheimers-like neurodegeneration, Advances in Geriatrics, vol. 2014, Article ID527518, 14 pages, 2014.
29. B. S. Berlett and E. R. Stadtman, Protein oxidation in aging, disease, and oxidative stress,The Journal of Biological Chemistry, vol. 272, no. 33, pp. 20313-20316, 1997.
30. D. A. Butterfield and E. R. Stadtman, Protein oxidation processes in aging brain, in Advances in Cell Aging and Gerontology, vol. 2, pp. 161-191, Elsevier, 1997.
31. K. J. Davies, Protein damage and degradation by oxygen radicals. I. general aspects, The Journal of Biological Chemistry, vol. 262, no. 20, pp. 9895-9901, 1987.
32. J. Cervera and R. L. Levine, Modulation of the hydrophobicity of glutamine synthetase by mixed-function oxidation, The FASEB Journal, vol. 2, no. 10, pp. 2591-2595, 1988.
33. K. J. A. Davies, Degradation of oxidized proteins by the 20S proteasome, Biochimie, vol. 83, no. 3-4, pp. 301-310, 2001.
34. K. D. Wilkinson, Regulation of ubiquitin-dependent processes by deubiquitinating enzymes,TheFASEB Journal, vol. 11,no. 14, pp. 1245-1256, 1997.
35. Y. Fang, D. Fu, and X. -Z. Shen, The potential role of ubiquitin c-terminal hydrolases in oncogenesis, Biochimica et Biophysica Acta, vol. 1806, no. 1, pp. 1-6, 2010.
36. J. H. Jara, D. D. Frank, and P. H. Ozdinler, Could dysregulation of UPS be a common underlying mechanism for cancer and neurodegeneration? Lessons from UCHL1, Cell Biochemistry and Biophysics, vol. 67, no. 1, pp. 45-53, 2013.
37. R. Setsuie and K. Wada, The functions of UCH-L1 and its relation to neurodegenerative diseases, Neurochemistry International, vol. 51, no. 2-4, pp. 105-111, 2007.
38. C. Das, Q. Q. Hoang, C. A. Kreinbring et al. , Structural basis for conformational plasticity of the Parkinsons diseaseassociated ubiquitin hydrolase UCH-L1, Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 12, pp. 4675-4680, 2006.
39. C. N. Larsen, B. A. Krantz, and K. D. Wilkinson, Substrate specificity of deubiquitinating enzymes: ubiquitin C-terminal hydrolases, Biochemistry, vol. 37, no. 10, pp. 3358-3368, 1998.
40. Y. Liu, L. Fallon, H. A. Lashuel, Z. Liu, and P. T. Lansbury Jr. , The UCH-L1 gene encodes two opposing enzymatic activities that affect α-synuclein degradation and Parkinsons disease susceptibility, Cell, vol. 111, no. 2, pp. 209-218, 2002.
41. H. Osaka, Y. -L. Wang, K. Takada et al. , Ubiquitin carboxyterminal hydrolase L1 binds to and stabilizes monoubiquitin in neuron, Human Molecular Genetics, vol. 12, no. 16, pp. 1945-1958, 2003.
42. C. J. Proctor, P. J. Tangeman, and H. C. Ardley, Modelling the role of UCH-L1 on protein aggregation in age-related neurodegeneration, PLoS ONE, vol. 5, no. 10, Article IDe13175, 2010.
43. H. Shen, M. Sikorska, J. Leblanc, P. R. Walker, and Q. Y. Liu, Oxidative stress regulated expression of ubiquitin Carboxylterminal Hydrolase-L1: role in cell survival, Apoptosis, vol. 11, no. 6, pp. 1049-1059, 2006.
44. K. Nishikawa, H. Li, R. Kawamura et al. , Alterations of structure and hydrolase activity of parkinsonism-associated human ubiquitin carboxyl-terminal hydrolase L1 variants, Biochemical and Biophysical Research Communications, vol. 304, no. 1, pp. 176-183, 2003.
45. A. Castegna, V. Thongboonkerd, J. Klein et al. , Proteomic analysis of brain proteins in the gracile axonal dystrophy (gad) mouse, a syndrome that emanates from dysfunctional ubiquitin carboxyl-terminal hydrolase L-1, reveals oxidation of key proteins, Journal ofNeurochemistry, vol. 88,no. 6, pp. 1540-1546, 2004.
46. A. Castegna, M. Aksenov, M. Aksenova et al. , Proteomic identification of oxidatively modified proteins in Alzheimers disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1, Free Radical Biology and Medicine, vol. 33, no. 4, pp. 562-571, 2002.
47. F. Di Domenico, R. Coccia, A. Cocciolo et al. , Impairment of proteostasis network in Down syndrome prior to the development of Alzheimers disease neuropathology: redox proteomics analysis of human brain, Biochimica et Biophysica Acta, vol. 1832, no. 8, pp. 1249-1259, 2013.
48. T. Kabuta, A. Furuta, S. Aoki, K. Furuta, and K. Wada, Aberrant interaction between Parkinson disease-associated mutant UCH-L1 and the lysosomal receptor for chaperone-mediated autophagy, The Journal of Biological Chemistry, vol. 283, no. 35, pp. 23731-23738, 2008.
49. T. Kabuta, R. Setsuie, T. Mitsui et al. , Aberrant molecular properties shared by familial Parkinsons disease-associated mutant UCH-L1 and carbonyl-modified UCH-L1, Human Molecular Genetics, vol. 17, no. 10, pp. 1482-1496, 2008.
50. G. M. Cole and P. S. Timiras, Ubiquitin-protein conjugates in Alzheimers lesions, Neuroscience Letters, vol. 79, no. 1-2, pp. 207-212, 1987.
51. G. Perry, R. Friedman, G. Shaw, and V. Chau, Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains, Proceedings of the National Academy of Sciences of the United States of America, vol. 84, no. 9, pp. 3033-3036, 1987.
52. H. Mori, J. Kondo, and Y. Ihara, Ubiquitin is a component of paired helical filaments inAlzheimers disease, Science, vol. 235, no. 4796, pp. 1641-1644, 1987.
53. L. Gregori, C. Fuchs, M. E. Figueiredo-Pereira, W. E. Van Nostrand, and D. Goldgaber, Amyloid α-protein inhibits ubiquitin-dependent protein degradation in vitro, The Journal of Biological Chemistry, vol. 270, no. 34, pp. 19702-19708, 1995.
54. J. N. Keller, K. B. Hanni, and W. R. Markesbery, Impaired proteasome function in Alzheimers disease, Journal of Neurochemistry, vol. 75, no. 1, pp. 436-439, 2000.
55. S. Oh, H. S. Hong, E. Hwang et al. , Amyloid peptide attenuates the proteasome activity inneuronal cells, Mechanisms of Ageing and Development, vol. 126, no. 12, pp. 1292-1299, 2005.
56. V. Cecarini, L. Bonfili, M. Amici, M. Angeletti, J. N. Keller, and A. M. Eleuteri, Amyloid peptides in different assembly states and related effects on isolated and cellular proteasomes, Brain Research, vol. 1209, pp. 8-18, 2008.
57. K. M. Rosen, C. E. -H. Moussa, H. -K. Lee et al. , Parkin reverses intracellular α-amyloid accumulation and its negative effects on proteasome function, Journal of Neuroscience Research, vol. 88, no. 1, pp. 167-178, 2010.
58. X. Hong, J. Liu, G. Zhu et al. , Parkin overexpression ameliorates hippocampal long-term potentiation and beta-amyloid load in an Alzheimers disease mousemodel, HumanMolecular Genetics, vol. 23, no. 4, pp. 1056-1072, 2014.
59. M. Kaneko, H. Koike, R. Saito, Y. Kitamura, Y. Okuma, and Y. Nomura, Loss of HRD1-mediated protein degradation causes amyloid precursor protein accumulation and amyloid-α generation, TheJournal ofNeuroscience, vol. 30,no. 11,pp. 3924-3932, 2010.
60. M. Zhang, Y. Deng, Y. Luo et al. , Control of BACE1 degradaton and APP processing by ubiquitin carboxyl-terminal hydrolase L1, Journal of Neurochemistry, vol. 120, no. 6, pp. 1129-1138, 2012.
61. D. A. Butterfield, M. Perluigi, and R. Sultana, Oxidative stress in Alzheimers disease brain: new insights from redox proteomics, European Journal of Pharmacology, vol. 545, no. 1, pp. 39-50, 2006.
62. I. Petropoulos, M. Conconi, X. Wang et al. , Increase of oxidatively modified protein is associated with a decrease of proteasome activity and content in aging epidermal cells, Journals of Gerontology-Series A: Biological Sciences and Medical Sciences, vol. 55, no. 5, pp. B220-B227, 2000.
63. P. E. Starke-Reed and C. N. Oliver, Protein oxidation and proteolysis during aging and oxidative stress, Archives of Biochemistry and Biophysics, vol. 275, no. 2, pp. 559-567, 1989.
64. P. A. Szweda, B. Friguet, and L. I. Szweda, Proteolysis, free radicals, and aging, Free Radical Biology and Medicine, vol. 33, no. 1, pp. 29-36, 2002.
65. T. Reinheckel,N. Sitte,O. Ullrich,U. Kuckelkorn,K. J. A. Davies, and T. Grune, Comparative resistance of the 20S and 26S proteasome to oxidative stress, Biochemical Journal, vol. 335, no. 3, pp. 637-642, 1998.
66. A. J. Rivett, Regulation of intracellular protein turnover: covalent modification as a mechanism of marking proteins for degradation, Current Topics in Cellular Regulation, vol. 28, pp. 291-337, 1986.
67. N. Sitte, M. Huber, T. Grune et al. , Proteasome inhibition by lipofuscin/ceroid during postmitotic aging of fibroblasts, The FASEB Journal, vol. 14, no. 11, pp. 1490-1498, 2000.
68. R. Sultana, D. Boyd-Kimball, H. F. Poon et al. , Redox proteomics identification of oxidized proteins in Alzheimers disease hippocampus and cerebellum: an approach to understand pathological and biochemical alterations in AD, Neurobiology of Aging, vol. 27, no. 11, pp. 1564-1576, 2006.
69. J. Choi, A. I. Levey, S. T. Weintraub et al. , Oxidative modifications and down-regulation of ubiquitin carboxylterminal hydrolase L1 associated with idiopathic Parkinsons and Alzheimers diseases, The Journal of Biological Chemistry, vol. 279, no. 13, pp. 13256-13264, 2004.
70. R. Saito, M. Kaneko, Y. Kitamura et al. , Effects of oxidative stress on the solubility of HRD1, a ubiquitin ligase implicated in Alzheimers disease, PLoS ONE, vol. 9, no. 5,Article IDe94576, 2014.
71. A. Castegna, M. Aksenov, V. Thongboonkerd et al. , Proteomic identification of oxidatively modified proteins in Alzheimers disease brain. Part II: dihydropyrimidinase-related protein 2, alpha-enolase and heat shock cognate 71, Journal of Neurochemistry, vol. 82, no. 6, pp. 1524-1532, 2002.
72. T. Uehara, T. Nakamura, D. Yao et al. , S-nitrosylated proteindisulphide isomerase links protein misfolding to neurodegeneration, Nature, vol. 441, no. 7092, pp. 513-517, 2006.
73. T. Nakamura, O. A. Prikhodko, E. Pirie et al. , Aberrant protein S-nitrosylation contributes to the pathophysiology of neurodegenerative diseases, Neurobiology of Disease, 2015.
74. V. Cecarini, Q. Ding, and J. N. Keller, Oxidative inactivation of the proteasome in Alzheimers disease, Free Radical Research, vol. 41, no. 6, pp. 673-680, 2007.
75. F. W. van Leeuwen, D. P. V. de Kleijn, H. H. van den Hurk et al. , Frameshift mutants of α amyloid precursor protein and ubiquitin-B in Alzheimers and Down patients, Science, vol. 279, no. 5348, pp. 242-247, 1998.
76. Y. A. Lam, C. M. Pickart, A. Alban et al. , Inhibition of the ubiquitin-proteasome system in Alzheimers disease, Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 18, pp. 9902-9906, 2000.
77. F. M. S. De Vrij, J. A. Sluijs, L. Gregori et al. , Mutant ubiquitin expressed in Alzheimers disease causes neuronal death, The FASEB Journal, vol. 15, no. 14, pp. 2680-2688, 2001.
78. A. D. Hope, R. De Silva, D. F. Fischer, E. M. Hol, F. W. Van Leeuwen, and A. J. Lees, Alzheimers associated variant ubiquitin causes inhibition of the 26S proteasome and chaperone expression, Journal of Neurochemistry, vol. 86, no. 2, pp. 394-404, 2003.
79. S. Song, S. -Y. Kim, Y. -M. Hong et al. , Essential role of E2-25K/Hip-2 in mediating amyloid-α neurotoxicity, Molecular Cell, vol. 12, no. 3, pp. 553-563, 2003.
80. Z. Chen and C. M. Pickart, A 25-kilodalton ubiquitin carrier protein (E2) catalyzesmulti-ubiquitin chain synthesis via lysine 48 of ubiquitin, The Journal of Biological Chemistry, vol. 265, no. 35, pp. 21835-21842, 1990.
81. P. van Tijn, F. J. A. Dennissen, R. J. G. Gentier et al. , Mutant ubiquitin decreases amyloid beta plaque formation in a transgenic mouse model of Alzheimers disease, Neurochemistry International, vol. 61, no. 5, pp. 739-748, 2012.
82. H. -C. Tai, A. Serrano-Pozo, T. Hashimoto, M. P. Frosch, T. L. Spires-Jones, and B. T. Hyman, The synaptic accumulation of hyperphosphorylated tau oligomers in alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system, American Journal of Pathology, vol. 181, no. 4, pp. 1426-1435, 2012.
83. J. Y. Zhang, S. J. Liu, H. L. Li, and J. -Z. Wang, Microtubuleassociated protein tau is a substrate of ATP/Mg2+-dependent proteasome protease system, Journal of Neural Transmission, vol. 112, no. 4, pp. 547-555, 2005.
84. D. Cripps, S. N. Thomas, Y. Jeng, F. Yang, P. Davies, and A. J. Yang, Alzheimer disease-specific conformation of hyperphosphorylated paired helical filament-Tau is polyubiquitinated through Lys-48, Lys-11, and Lys-6 ubiquitin conjugation, The Journal of Biological Chemistry, vol. 281, no. 16, pp. 10825-10838, 2006.
85. F. Gillardon, A. Klo, M. Berg et al. , The 20S proteasome isolated from Alzheimers disease brain shows post-translational modifications but unchanged proteolytic activity, Journal of Neurochemistry, vol. 101, no. 6, pp. 1483-1490, 2007.
86. Y. X. Shen, A. M. Sun, S. Fang et al. , Hrd1 facilitates tau degradation and promotes neuron survival, Current Molecular Medicine, vol. 12, no. 2, pp. 138-152, 2012.
87. D. Poppek, S. Keck, G. Ermak et al. , Phosphorylation inhibits turnover of the tau protein by the proteasome: influence of RCAN1 and oxidative stress, Biochemical Journal, vol. 400, no. 3, pp. 511-520, 2006.
88. H. Shimura, D. Schwartz, S. P. Gygi, and K. S. Kosik, CHIPHsc70 complex ubiquitinates phosphorylated tau and enhances cell survival,The Journal of Biological Chemistry, vol. 279, no. 6, pp. 4869-4876, 2004.
89. L. Petrucelli, D. Dickson, K. Kehoe et al. , CHIP andHsp70 regulate tau ubiquitination, degradation and aggregation, Human Molecular Genetics, vol. 13, no. 7, pp. 703-714, 2004.
90. T. Grune, D. Botzen, M. Engels et al. , Tau protein degradation is catalyzed by the ATP/ubiquitin-independent 20S proteasome under normal cell conditions, Archives of Biochemistry and Biophysics, vol. 500, no. 2, pp. 181-188, 2010.
91. Q. Huang, H. Wang, S. W. Perry, and M. E. Figueiredo-Pereira, Negative regulation of 26S proteasome stability via calpainmediated cleavage of Rpn10 subunit upon mitochondrial dysfunction in neurons, The Journal of Biological Chemistry, vol. 288, no. 17, pp. 12161-12174, 2013.
92. M. Ghanevati and C. A. Miller, Phospho-beta-catenin accumulation in Alzheimers disease and in aggresomes attributable to proteasome dysfunction, Journal of Molecular Neuroscience, vol. 25, no. 1, pp. 79-94, 2005.
93. P. Kurup, Y. Zhang, J. Xu et al. , Aα-mediated NMDA receptor endocytosis in alzheimers disease involves ubiquitination of the tyrosine phosphatase STEP61, The Journal of Neuroscience, vol. 30, no. 17, pp. 5948-5957, 2010.
94. J. N. Keller, K. B. Hanni, and W. R. Markesbery, Possible involvement of proteasome inhibition in aging: implications for oxidative stress, Mechanisms of Ageing and Development, vol. 113, no. 1, pp. 61-70, 2000.
95. J. N. Keller, J. Gee, and Q. Ding, The proteasome in brain aging, Ageing Research Reviews, vol. 1, no. 2, pp. 279-293, 2002.
96. M. Paz Gavilan, J. Vela, A. Castaño et al. , Cellular environment facilitates protein accumulation in aged rat hippocampus, Neurobiology of Aging, vol. 27, no. 7, pp. 973-982, 2006.
97. J. N. Keller, F. F. Huang, andW. R. Markesbery, Decreased levels of proteasome activity and proteasome expression in aging spinal cord, Neuroscience, vol. 98, no. 1, pp. 149-156, 2000.
98. V. Goder, Roles of ubiquitin in endoplasmic reticulumassociated protein degradation (ERAD), Current Protein and Peptide Science, vol. 13, no. 5, pp. 425-435, 2012.
99. A. E. Cartier, S. N. Djakovic, A. Salehi, S. M. Wilson, E. Masliah, andG. N. Patrick, Regulationof synaptic structure byubiquitin C-terminal hydrolase L1, The Journal of Neuroscience, vol. 29, no. 24, pp. 7857-7868, 2009.
100. F. Chen, Y. Sugiura, K. G. Myers, Y. Liu, andW. Lin, Ubiquitin carboxyl-terminal hydrolase L1 is required for maintaining the structure and function of the neuromuscular junction, Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 4, pp. 1636-1641, 2010.
101. M. Zhang, F. Cai, S. Zhang, S. Zhang, andW. Song, Overexpression of ubiquitin carboxyl-terminal hydrolase L1 (UCHL1) delays Alzheimers progression in vivo, Scientific Reports, vol. 4, article 7298, 2014.
102. B. Gong, Z. Cao, P. Zheng et al. , Ubiquitin hydrolase Uch-L1 rescues beta-amyloid-induced decreases in synaptic function and contextualmemory, Cell, vol. 126, no. 4, pp. 775-788, 2006.
103. D. A. Butterfield, Oxidative stress in neurodegenerative disorders, Antioxidants and Redox Signaling, vol. 8, no. 11-12, pp. 1971-1973, 2006.
104. K. S. Montine, P. J. Kim, S. J. Olson, W. R. Markesbery, and T. J. Montine, 4-Hydroxy-2-nonenal pyrrole adducts in human neurodegenerative disease, Journal of Neuropathology and Experimental Neurology, vol. 56, no. 8, pp. 866-871, 1997.
105. R. J. Castellani, G. Perry, S. L. Siedlak et al. , Hydroxynonenal adducts indicate a role for lipid peroxidation in neocortical and brainstem Lewy bodies in humans, Neuroscience Letters, vol. 319, no. 1, pp. 25-28, 2002.
106. D. A. Butterfield, H. F. Poon, D. St. Clair et al. , Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: insights into the development of Alzheimers disease, Neurobiology of Disease, vol. 22, no. 2, pp. 223-232, 2006.
107. M. Perluigi, F. DiDomenico, andD. A. Buttterfield, Unraveling the complexity of neurodegeneration in brains of subjects with Down syndrome: insights from proteomics, Proteomics-Clinical Applications, vol. 8, no. 1-2, pp. 73-85, 2014.